Improved Understanding of Genomics Drives Excitement in High

At present, there are no FDA-approved systemic therapies for patients with high-grade meningiomas. However, there has been an increase in research surrounding the disease over the past decade, which is improving the prospect a targeted agent may become for this population.

Related Keywords

Massachusetts , United States , Nader Sanai , Priscilla Kaliopi Brastianos , Harvard Medical School , World Health Organization , Hospital Cancer Center , Ivy Brain Tumor Center , National Cancer Institute , Barrow Neurological Institute , National Cancer Institute Cooperative Group , Ivy Center , Kaliopi Brastianos , Massachusetts General Hospital Cancer Center , World Health , Barrow Neurological , Treatments Move Closer , Fda Approved Systemic Therapies For Patients With High Grade Meningiomas , Genomics , Molecular Drivers , Brain Cancer ,